|
GENERIC
|
Netarsudil 0.02% | Latanoprost 0.005%
|
|
INDICATIONS
|
Reduction of elevated intraocular pressure (IOP)
|
|
MECHANISM OF ACTION
|
Increase aqueous outflow and reduces aqueous production
|
|
MICROBIOLOGY
|
Acts on RHO kinase and norepineprine transporters found on trabecular meshwork. Also works on uveoscleral pathway as prostaglandin analogue.
|
|
CONTRAINDICATIONS & WARNINGS
|
No contraindications but Rocklatan can cause an increase in pigmentation of the iris, periorbital tissues and eyelashes. Can increase eyelash length. Can cause macular edema. Avoid in patients with a history of herpetic keratitis.
|
|
PEDIATRIC USE
|
Safety and effectiveness in pediatric patients have not been established
|
|
PREGNANCY
|
There are no adequate and well-controlled studies of ROCKLATAN ophthalmic solution or its pharmacologically active ingredients (netarsudil and latanoprost) in pregnant women to inform any drug associated risk.
|
